Form 4: Oncology Institute Director Reports Share Distribution

Oncology Institute Director Gabriel Ling reported changes in beneficial ownership of common stock through an in-kind distribution.

Summary

• Director and 10% Owner Gabriel Ling reported a transaction involving Oncology Institute, Inc. common stock.
• The transaction occurred on November 18, 2025, and was filed on November 20, 2025.
• Ling acquired 141,149 shares of common stock.
• Ling disposed of 250,206 shares of common stock.
• These changes resulted from an in-kind distribution by M33 Growth I, L.P. to its limited partners, including Gabriel Ling, on a pro rata basis.
• The transaction was made pursuant to a Rule 10b5-1 plan.

Sentiment

Score: 5

Explanation: The transaction is an in-kind distribution from a fund to a director, which is a change in the form of ownership rather than a direct market buy or sell. While there's a net disposition of shares, it's part of a pre-arranged distribution, making the sentiment neutral to slightly negative depending on interpretation of the net change.

Positives

• The transaction was executed under a Rule 10b5-1 plan, indicating a pre-arranged, non-discretionary transaction.

Negatives

• The disposition of 250,206 shares, exceeding the 141,149 shares acquired, results in a net reduction of shares beneficially associated with the director and 10% owner. While part of an in-kind distribution, a net decrease in insider holdings could be perceived negatively by some investors.

Future Outlook

The filing does not provide a future outlook for the company's performance or strategy, focusing solely on an insider's ownership change.

Industry Context

This filing pertains to an individual insider's share ownership changes and does not provide information directly related to broader industry trends or competitive landscape.

Related Party Transactions

• The transaction involves an in-kind distribution from M33 Growth I, L.P. to its limited partners, including Gabriel Ling. As Gabriel Ling is a Director and 10% Owner of Oncology Institute, Inc., and likely has an interest in M33 Growth I, L.P., this constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The transaction results in a change in the beneficial ownership structure of a significant insider, potentially impacting perceptions of insider alignment, though it's a pre-planned distribution rather than a discretionary sale.
• Gabriel Ling: The transaction alters the direct and indirect holdings of common stock for the reporting person.

Key Dates

Keywords

Oncology Institute, TOI, Gabriel Ling, Form 4, Insider Trading, Beneficial Ownership, Share Distribution, M33 Growth I, L.P., Rule 10b5-1